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Introduction
============

The management of spinal column metastasis has increasingly moved towards less invasive separation surgery followed by adjuvant stereotactic radiosurgery (SRS). This decompressive approach reduces the post-operative recovery burden while preserving high levels of functional independence \[[@REF1], [@REF2]\]. However, aggressive surgical stabilization and construct extension is still warranted among destabilizing and multiply-recurrent pathologies for preservation of function. The advantages and disadvantages of these large spinal constructs in already poor quality bone subject to further irradiation, become important in the pre-operative discussion.

Despite its radiobiological stressors, SRS is with known benefits toward pain and disease control \[[@REF3]-[@REF5]\]. The movement from adjuvant external radiation therapy (XRT) to SRS for spinal column metastasis provides higher doses with steeper drop-offs limiting direct radiation to the bony matrix and spinal cord \[[@REF1], [@REF6], [@REF7]\]. Nevertheless, the long oncologic course for these patients exposes them to multiple treatment sessions and multiple modalities of radiation that additively undermine desirable fusion. Concerns for decreased periosteal osteoblastic proliferation, decreased vascularity, and increased bony pliancy subject patients to the risks of hardware failure, including implant migration, fusion failure, and biomechanical destabilization-associated pain that can warrant surgical revision \[[@REF8], [@REF9]\].

Unfortunately, the reduced life expectancies and post-operative tolerances of the overall spinal tumor population has made an assessment of post-SRS pseudarthrosis difficult. Furthermore, published series are limited by their partial reporting of radiation treatment history or follow-up, leading to a wide range of pseudarthrosis rates that are difficult to compare. Thus, the collective impact of serial, surgical and adjuvant radiation treatments on surgical decision-making is absent. Therefore, we assessed patients with perioperative SRS for recurrent spinal column metastasis necessitating instrumentation to qualify how the rates of radiographic and clinical pseudarthrosis guide their oncologic management.

Materials and methods
=====================

Patient population

A retrospective review of a prospectively collected database of patients treated with non-isocentric SRS between October 2002 and May 2013 was performed. We limited assessment to patients with instrumented fusion with post-surgical SRS radiation, and at least six months of radiographic follow-up. From a total of 418 patients who were treated with SRS, 42 (10%) were with prior surgery and instrumentation, 35 (8.4%) with Karnofsky performance score (KPS) \> 70, and 11 (2.6%) patients who met criteria for inclusion.

Primary outcome measured for the rate hardware failure, including radiographic and clinical pseudarthrosis, as well as the rate of operative externalization. Demographic and risk factors including sex, age at treatment, weight, smoking history, osteoporosis, primary disease histology, and KPS at time of index SRS treatment were recorded. All aspects of the study were performed in accordance with relevant guidelines and regulations as were approved by the Stanford Institute Review Board. Written informed consent was not required given the retrospective study format.

Treatment

Surgical and SRS treatment history were characterized for analysis. All instrumented and non-instrumented fusions to the spine were documented. Individual surgical interventions were further assessed for indication, need for instrumentation, time from any preceding SRS or instrumented surgery, location relative to prior surgery, symptoms prior to treatment, response to treatment, surgical approach as well as incorporation of corpectomy, junctional levels, and graft.

Regarding radiation treatment, all sessions with exposure to the spine by either conventional radiation therapy or SRS were documented. Individual SRS interventions, which were all performed at the authors' institution, were further assessed for indication, levels treated, time from index instrumented-surgery, time from prior SRS, location relative to prior SRS, symptoms prior to SRS, and response to treatment. Biological equivalent doses were estimated with an alpha/beta of 10.

Statistical analyses

Differences in means and proportions were determined by Mann-Whitney/un-paired t-test. Probabilistic univariate and multivariate analyses were performed by logistic regressions. Statistical analyses were performed using Stata/SE 13.1 Software (StataCorp, College Station, TX, USA). Statistical significance was targeted for p \< 0.05.

Results
=======

For the 11 patients who met inclusion criteria, mean radiographic follow-up was 48.9 (6-121) months. Assessment of primary outcomes identified four (36%) patients with hardware failure, within which 3/11 (27%) were with radiographically confirmed pseudarthrosis (Table [1](#TAB1){ref-type="table"}). Among these patients, externalization was performed in one (9%) patient for screw loosening, which ultimately was attributed to tumor involvement. Clinically attributed neck pain was reported in 1/11 (9%), but no pseudarthrosis was detected and no revision was performed. Individual risk factors included 1/11 (9%) patients with osteoporosis, 4/11 (36%) with former smokers (none current), and 7/11 (64%) with elevated body mass index (BMI). All patients underwent chemotherapy after SRS, but 5/11 (45%) had not initiated a regimen beforehand. Two (18%) patients were with protracted steroid treatment. Three (27%) patients had unfavorable histologies, including one with lung and two with prostate primaries. The remaining patients were treated for breast, melanoma, thyroid, thymoma, and multiple myeloma \[[@REF7]\].

###### Surgical instrumentation, peri-operative timeline, and fusion features.

CK: CyberKnife; F: Female; Gy: Gray; M: Male; NA: Not applicable; NSCLC: Non-small cell lung cancer; mo: month; RCC: Renal cell carcinoma; yr: year.

  ------ ----- ------------------ ------------------- ---------------------------------------------------- ------------- ------------- ---------------------- --------------------------------------- ------------------------------------- -------------------------------------------------- ------------ -------------------------------------------------------------- -----------------------------
  Case   Sex   Histology          Instrument Levels   Procedure                                            Indication    Disposition   Age at 1^st^ CK (yr)   Time to CK from 1^st^ Instrument (mo)   Time to 2^nd^ CK from 1^st^ CK (mo)   Time to 2^nd^ Surgery from 1^st^ Instrument (mo)   Graft        Hardware Failure                                               Radiographic Follow-up (mo)
  1      F     NSCLC              C5-7                Corpectomy, ACDF                                     Unstable      NA            57                     21                                      13                                    34                                                 Allograft    Pseudarthrosis: After all procedures                           34
                                  C5-6                Corpectomy Foraminotomy                              Compression   Home                                                                                                                                                                  Unreported                                                                   
  2      F     Breast             O-C4                Lateral mass osteotomy, Posterior fusion             Unstable      Home          68                     0                                       61                                                                                       Both         Pseudarthrosis: After index instrumentation and adjuvant SRS   56
  3      F     Breast             C1-4                Posterior fusion                                     Unstable      Home          58                     2                                                                                                                                Allograft    N                                                              56
  4      M     RCC                L2-4                Corpectomy, Posterior fusion                         Unstable      Home          59                     6                                       5                                     18                                                 Both         Externalized: At second instrumentation                        30
                                  T10-S1              Posterior fusion, Removal of prior instrumentation   Compression   Home                                                                                                                                                                  Autograft                                                                    
  5      M     RCC                T10-12 T8-L2        Corpectomy, Anterior and Poster Fusion,              Unstable      Rehab.        66                     0                                       10                                                                                       Allograft    N                                                              34
  6      M     Melanoma           NA                  \[Laminectomy\]                                      NA            NA            56                     3                                       7                                     11                                                 NA           N                                                              19
                                  C7-T9               Posterior fusion                                     Compression   Home                                                                                                                                                                  Unreported                                                                   
                                  C5-T8               Posterior fusion                                     Compression   Home                                                                                                                                                                  Allograft                                                                    
                                  T3-T5               Corpectomy, Posterior fusion                         Compression   Home                                                                                                                                                                  Allograft                                                                    
  7      M     Melanoma           NA                  \[Aborted resection\]                                NA            NA            49                     1                                       14                                    9                                                  NA           N                                                              21
                                  T2-T7               Posterior fusion                                     Compression   Home                                                                                                                                                                  Both                                                                         
                                  T3-T7               Corpectomy, Anterior and Posterior fusion            Compression   Home                                                                                                                                                                  Both                                                                         
                                  NA                  \[Laminectomy\]                                      NA            Rehab.                                                                                                                                                                                                                                             
  8      M     Melanoma           NA                  \[Uninstrumented resection\]                         NA            NA            74                     6                                       4                                                                                        NA           N                                                              62
                                  NA                  \[Uninstrumented resection\]                         NA            NA                                                                                                                                                                    NA                                                                           
                                  C7-T2               Posterior fusion                                     Compression   Home                                                                                                                                                                  Both                                                                         
  9      F     Thyroid            T4-T8               Corpectomy, Posterior fusion                         Unstable      Home          64                     16                                      44                                                                                       Allograft    Pseudarthrosis: After all procedures                           121
  10     M     Thymoma            T6-T10              Corpectomy, Posterior fusion                         Compression   Home          41                     1                                                                                                                                Allograft    N                                                              6
                                  NA                  \[Laminectomy\]                                      NA            NA                                                                                                                                                                    NA                                                                           
  11     M     Multiple Myeloma   T4-T8               Posterior fusion                                     Compression   Home          34                     38                                      61                                                                                       Allograft    N                                                              99
  ------ ----- ------------------ ------------------- ---------------------------------------------------- ------------- ------------- ---------------------- --------------------------------------- ------------------------------------- -------------------------------------------------- ------------ -------------------------------------------------------------- -----------------------------

There were a total of 21 sessions of non-isocentric hypofractionated treatment of spinal SRS, all treated by CyberKnife at the authors' institution, and 12 sessions of spinal RT (Table [2](#TAB2){ref-type="table"}). After index SRS, nine (82%) patients underwent repeat SRS and one (9%) patient required a third session. Time to SRS after first instrumented surgery was median three (0-38) months. A mean 1.0 (1-3) and 2.5 (1-3) levels were treated at first and second SRS, respectively. Median time to second SRS was 13.0 months (4-61). Among the eight repeat treatment plans, one took place at a distinctly separate spinal distribution. SRS treatment plans were with median 24 Gy (16-35) prescription dose, in median three fractions (1-5) to the 80% (70-84) isodose line with a median maximum dose of 29.3 Gy (20.5-43.8). A median 23.5 cc (0.77-247) was treated with a median conformity index of 1.35 (1.1-2.04). Notably, the biological equivalent dose (BED) for those without instrumentation failure was higher, with median BED for those with and without failure at 51.3 (40-70.4) Gy vs 42.4 (35.7-50.4) Gy (p = 0.0051), respectively.

###### Radiation planning and radiation history.

cc: Cubic centimeter; CI: Conformity index; CK: CyberKnife; Gy: Gray; IMRT: Intensity-modulated radiation therapy; NA: Not applicable; mo: month; yr: year.

  ------ ------------ ----------------- ------------ ------------------------ ----------- --------------- ------------- ------ -------------------------------------------------------------------
  Case   CK Session   Indication        SRS Target   Prescription Dose (Gy)   Fractions   Max Dose (Gy)   Volume (cc)   CI     Other Radiation Treatment
  1      1st          Progression       C1-2         24                       3           29.27           17.13         1.61   Once, after index instrumentation
         1st                            C5-6         24                       3           29.63           17.79         1.68    
         2nd          Residual          C6           20                       2           26.32           12.35         1.28    
  2      1st          Residual          C2           25                       5           31.25           30.83         1.48   NA
         2nd          Progression       C1-3         27                       3           33.75           60.80         1.10    
  3      1st          Primary Control   C2           24                       3           30              13.76         1.29   Twice, after index instrumentation/adjuvant SRS
  4      1st          Progression       T12          21                       3           25.82           6.20          1.63   Once, prior to index instrumentation
         1st                            L1           21                       3           26.25           26.20         1.73   NA
         1st                            L2           21                       3           26.04           23.50         1.52    
         2nd          Progression       L3           24                       3           32              8.46          1.27    
  5      1st          Residual          T11          22                       1           28.2            100.67        1.23   NA
         2nd          Progression       L1           20                       1           25              42.69         1.22    
         2nd                            L4           20                       1           25              46.14         1.16    
  6      1st          Boost             T4           16                       1           20.51           5.11          1.54   Once, before index instrumentation
         2nd          Residual          T4           20                       2           23.80           12.56         1.28    
  7      1st          Residual          T5           27                       3           36.48           33.48         1.48   Once, before index instrumentation
         2nd          Residual          T5           35                       5           43.75           74.08         1.12    
  8      1st          Progression       L3-4         20                       2           25.64           0.85          2.04   Twice, after first and second instrumentation
         2nd          Progression       C1-2         24                       3           30              0.77          1.59    
  9      1st          Progression       T6           27                       4           35.06           21.04         1.35   IMRT, after 3^rd^ CK
         2nd          Progression       T4-6         18                       1           24              34.08         1.35    
         3rd          Progression       T3           18                       1           23.68           6.28          1.26    
  10     1st          Residual          T8           27                       3           38.57           30.75         1.86   Once, after second instrumentation
  11     1st          Progression       T4           27                       3           34.61           35.77         1.20   Twice, after index instrumentation as adjuvant and after 1^st^ CK
         2nd          Progression       T9-11        24                       3           30              247           1.29    
  ------ ------------ ----------------- ------------ ------------------------ ----------- --------------- ------------- ------ -------------------------------------------------------------------

Reason for SRS at the index treatment was for residual tumor in 4/11 (36%) patients and for tumor progression in 5/11 (45%) patients. An additional one (9%) patient underwent SRS initially for primary control, and one (9%) for boost treatment. Second SRS was indicated for residual tumor and progression in 3/9 (33%) and 6/9 (67%) patients, respectively. Among those requiring repeat SRS treatment, 1/8 (12.5%) underwent SRS at a distinctly different spinal segment. There were 10/11 (91%) and 7/9 (78%) patients with symptoms at first and second SRS, and 8/11 (73%) and 2/7 (29%) with subsequent improvement. Two patients were without follow-up after their second SRS treatment.

A total of 16 decompressive procedures were performed. An unstable spine was identified in 6/11 (55%) at initial presentation, and all repeat surgeries (6/6) were for decompression. Time to second surgery was median 14.5 (9-34) months. A mean 5.4 (2-10) and 3.75 (2-5) levels were treated on first and second surgery, respectively. Among the four patients who had a repeat procedure involving instrumentation, one took place at a distant spinal segment. Symptomatic improvement was experienced by 9/11 (82%) and 1/4 (25%) patients following their initial and second instrumented surgeries, respectively. Among index procedures, 5/11 (45%) patients underwent a corpectomy and 4/11 (36%) took place at a junctional level. Allograft-alone was utilized in 6/11 (54%) index procedures, as well as in 1/4 (25%) and 1/1 of second and third procedures, respectively. At the time of discharge, 14/16 (87.5%) dispositions were to home.

Discussion
==========

Current improvements in oncologic care will yield prolonged survival that demands recurrent considerations for instrumented stabilization and risks of revision \[[@REF10]\]. Here we characterized the heterogeneous and complex clinical histories of patients with extended follow-up and determine that pseudarthrosis remains a prominent risk, as 27% were with radiographic evidence of lucency. However, a complete survey of their clinical courses suggests that patients with spinal metastasis tolerate aggressive surgical management with perioperative SRS, and may present with progression and urgent decompression needs that outpace competing hardware risks.

Variations in surgical approaches, radiographic follow-up and timing of adjunct radiation treatment make comparisons difficult between published studies, but our pseudarthrosis rate is consistent with the reported 0-43%. On the lower range, Harel et al. identified no instrumentation failure (0/8) with a more conservative median 14.75 Gy single fraction treatment at median 15.9 months, while Amankulor et al. reported a 2.8% (9/318) symptomatic hardware failure rate at a median 19 months, all with compression fractures perhaps related to long and/or posterior-only stabilization \[[@REF11], [@REF12]\]. Aside from our broader criteria, a higher pseudarthrosis rate in our series may be attributed to longer follow-up and inclusion of patients' multiple courses of radiation, thereby capturing the lifelong pseudarthrosis rate.

Higher instrumentation failure rates were reported in earlier XRT studies where perhaps dosing regimens had not yet been optimized \[[@REF8], [@REF11]\]. Emery et al. noted that patients with pseudarthrosis were all with total XRT \> 40 Gy, but the statistical significance of this threshold was eliminated once converted to BED \[[@REF8]\]. The more contemporary option for SRS with higher prescription doses is largely preferable to XRT to achieve local control \[[@REF1], [@REF7], [@REF11]\]. This could preserve bony integrity and preclude implant externalization, as was necessary in one of our patients and which our BED analysis supports, perhaps obviating stress-imposing extension of constructs as in one of our cases \[[@REF11]\].

Most importantly, our review further qualifies the role of perioperative SRS despite hardware risks \[[@REF13], [@REF14]\]. We see that radiographic pseudarthrosis is more prominent than symptomatic failure. Time to pseudarthrosis occurred at 36, 54, and 117 months, which was longer than the median time to retreatment. The benefits to quality of life are evident in the rate of symptomatic improvements and the rate at which they discharge to home. In the same vein, Laufer et al. reported an optimistic functional status following repeat posterolateral decompression (without radiation), with 65% still ambulatory at the time of last follow-up and with unchanged rates of estimated survival \[[@REF6]\].

Our results and prior work will help counsel patients with recurring pathology and spinal surgeries. Local recurrence is estimated to affect a quarter of patients \[[@REF6], [@REF14], [@REF15]\]. Likewise, re-operation is anticipated for 25% of spinal metastasis patients. Although pseudarthrosis currently does not appear to fully correlate with symptomatic failure, there is the future risk that with prolonged survival, patients will increasingly experience pain associated with instrumentation and perioperative SRS. Post-operative radiation is known to have detrimental effects on fusion, particularly in the early post-operative period \[[@REF16], [@REF17]\].­ If patients are anticipated to experience multiple procedures, such as those with favorable pathologies, perhaps more frequent spinal imaging should be obtained in select populations to provide neoadjuvant SRS.

Conclusions
===========

Here we provide a complete longitudinal assessment of patients with instrumented metastatic spinal disease who required re-operation and re-irradiation, not captured in prior works. We suspect symptomatic pseudarthrosis rate is an overestimate of the problem given the number of patients lost to follow-up due to survival. We anticipate with the improvement of individualized therapy and increased availability for SRS treatment, future studies will offer greater follow-up and sample size for statistical assessment. While we reaffirm a genuine risk for pseudarthrosis following perioperative SRS, the associated symptoms are minimal and should not deter aggressive radiation and surgical management if with good prognosis.
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